Nintedanib is a small-molecule tyrosine kinase inhibitor marketed as Ofev for fibrosing interstitial lung diseases. It is used in idiopathic pulmonary fibrosis and progressive fibrosing ILD settings, including systemic sclerosis-associated ILD. The FDA first approved Ofev on October 15, 2014.
Deupirfenidone, a deuterated form of pirfenidone, is set to be tested in a phase 3 trial this year after successful phase 2b results. The FDA and European Commission have granted orphan drug designation to support its late-stage development.
DelveInsight releases three separate pipeline reports covering metastatic prostate cancer (80+ companies, 85+ drugs), iPSC-derived NK cells (12+ companies, 15+ drugs), and interstitial lung diseases (120+ companies, 120+ drugs), highlighting recent regulatory approvals, trial launches, and emerging therapies.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07080125 |
A Study Using a Disease Registry to Observe the Long-term Effects of Nintedanib in People With Scleroderma-related Lung Fibrosis |
ACTIVE_NOT_RECRUITING | |
| NCT05262751 |
A Study in Healthy Men to Find the Best Formulation for Once Daily Intake of Nintedanib |
COMPLETED | PHASE1 |
| NCT04614441 |
NICEFIT-ON: A Study Under Routine Clinical Practice in Taiwan to Observe the Long-term Outcome of People With Certain Types of Lung Disease (PF-ILD, SSc-ILD, IPF) Who Start Treatment With Nintedanib |
COMPLETED |
